个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Revision surgery versus biologic treatment with omalizumab in recurrent chronic rhinosinusitis with nasal polyps: An analysis of cost-utility and clinical outcomes

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Sima Yutong[1,2] * ; Zhang Jing[1,2,3] * ; Zheng Ming[1] ; Zhao Yan[1,2] ; Wang Xiangdong[1,2,4,*2] ; Zhang Luo[1,2,4,5,*1] ;
机构： [1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. [2]Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China. [3]Department of Otolaryngology Head and Neck Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. [4]Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. [5]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing 100005, China.
出处：
DOI： 10.1016/j.waojou.2023.100846
ISSN：

关键词： Recurrent chronic rhinosinusitis with nasal polyps Omalizumab Revision surgery SNOT-22 Economic cost Duration cost

摘要：
Both revision surgery and omalizumab are recommended therapies for the treatment of recurrent chronic rhinosinusitis with nasal polyps (CRSwNP) and can improve patients' clinical symptoms and quality of life (QoL). The aim of this study was to compare the improvement in sinus-related symptoms, QoL, economic cost, and duration cost between treatment with revision-surgery and treatment with omalizumab.This was a prospective study of patients with recurrent CRSwNP. All patients were asked to complete a 22-item sino-nasal outcome test (SNOT-22), a visual analog scale (VAS), and a 36-item short-form (SF-36) questionnaire at baseline and 6 months after the treatments. Patients were required to document economic costs and duration costs within 6 months and report them at each visit.A total of 44 patients who received the treatment of revision surgery or omalizumab were enrolled in this study. After six months of treatment, the improvements in total SNOT-22 and SF-36 in 8 domains were not different between the 2 treatments. The improvements in rhinologic symptoms, extranasal rhinologic symptoms, and ear/facial symptoms according to the SNOT-22 (P value = 0.0288, 0.0016, and 0.0347, respectively) and the improvements in nasal congestion, loss of smell, and overall symptoms assessed by the VAS (P value = 0.0057, 0.0206, and 0.0122, respectively) were better in the revision surgery group than in the omalizumab group. The economic cost and the total duration cost were obviously lower in the omalizumab group (¥18836 and 1 day) than in the revision surgery group (¥29824 and 23 days).Both revision surgery and omalizumab treatments can improve the clinical symptoms and QoL of patients with recurrent CRSwNP. Patients who underwent revision surgery experienced better improvement in sinus-related symptoms. However, omalizumab treatment clearly showed a benefit in terms of economic cost and duration cost of disease-related care.© 2023 The Author(s).

基金：
This project was supported by the National Key R&D Program of China (2022YFC2504100), the Program for the Changjiang Scholars and Innovative Research Team (IRT13082), the National Natural Science Foundation of China (82171110, 82000962, and 81970852), the CAMS Innovation Fund for Medical Sciences (2019-I2M-5–022), the Capital’s funds for health improvement and research (2022-1-1091), the Beijing Natural Science Foundation (7222024), the Beijing New-star Plan of Science and Technology (20220484226), the Beijing Hospitals Authority Youth Program (QML20230201), the Public Welfare Development and Reform Pilot Project (2019-10), the Beijing Municipal Science & Technology Commission (Z211100002921057) and the Special Funds for the Construction of High-level Public Health Technical Talents (Lingjunrencai-01-08 and Lingjunrencai-02-09).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 3 区 医学
小类 | 3 区 过敏 3 区 免疫学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 过敏 2 区 免疫学
JCR分区：
出版当年[2021]版：
Q2 ALLERGY Q2 IMMUNOLOGY
最新[2023]版：
Q2 ALLERGY Q2 IMMUNOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. [2]Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. [2]Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China. [4]Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. [5]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing 100005, China. [*1]Department of Otorhinolaryngology Head and Neck Surgery and Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China [*2]Department of Otorhinolaryngology Head and Neck Surgery and Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
推荐引用方式(GB/T 7714)：
Sima Yutong,Zhang Jing,Zheng Ming,et al.Revision surgery versus biologic treatment with omalizumab in recurrent chronic rhinosinusitis with nasal polyps: An analysis of cost-utility and clinical outcomes[J].WORLD ALLERGY ORGANIZATION JOURNAL.2023,16(12):doi:10.1016/j.waojou.2023.100846.
APA：
Sima Yutong,Zhang Jing,Zheng Ming,Zhao Yan,Wang Xiangdong&Zhang Luo.(2023).Revision surgery versus biologic treatment with omalizumab in recurrent chronic rhinosinusitis with nasal polyps: An analysis of cost-utility and clinical outcomes.WORLD ALLERGY ORGANIZATION JOURNAL,16,(12)
MLA：
Sima Yutong,et al."Revision surgery versus biologic treatment with omalizumab in recurrent chronic rhinosinusitis with nasal polyps: An analysis of cost-utility and clinical outcomes".WORLD ALLERGY ORGANIZATION JOURNAL 16..12(2023)

相关文献

[1]Cost-utility and clinical outcome analysis of surgery or oral corticosteroids treatment in patients with chronic rhinosinusitis with nasal polyps [2]Predictive Significance of Charcot-Leyden Crystal Protein in Nasal Secretions in Recurrent Chronic Rhinosinusitis with Nasal Polyps [3]Predictive Significance of Charcot-Leyden Crystal Protein in Nasal Secretions in Recurrent Chronic Rhinosinusitis with Nasal Polyps. [4]抗ige单克隆抗体治疗合并哮喘的复发性慢性鼻窦炎伴鼻息肉的短期疗效研究 [5]Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma [6]Over-expression of CRTH2 indicates eosinophilic inflammation and poor prognosis in recurrent nasal polyps [7]A retrospective review of cochlear implant revision surgery: a 24-year experience in China [8]Economic evaluation of combined population-based screening for multiple blindness-causing eye diseases in China: a cost-effectiveness analysis [9]Revision surgery after pregnancy in a patient with congenital kyphoscoliosis A case report [10]The Efficacy of Preseasonal Omalizumab Treatment

资源点击量：25471 今日访问量：0 总访问量：1498 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)